Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$120.14 USD

120.14
4,928,181

+0.12 (0.10%)

Updated Aug 13, 2025 04:00 PM ET

After-Market: $120.15 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (146 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Are Options Traders Betting on a Big Move in Gilead (GILD) Stock?

by Zacks Equity Research

Investors need to pay close attention to Gilead (GILD) stock based on the movements in the options market lately.

Zacks Equity Research

Gilead to Buy Immuno-Oncology Company Forty Seven for $4.9B

by Zacks Equity Research

Gilead (GILD) looks to strengthen its immuno-oncology research and development portfolio with the acquisition of Forty Seven.

Kinjel Shah headshot

Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work

by Kinjel Shah

President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.

Zacks Equity Research

Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA

by Zacks Equity Research

Pfizer (PFE) identifies potential antiviral compounds to develop a treatment for coronavirus disease. The FDA accepts regulatory application seeking approval for tanezumab for osteoarthritis.

Kinjel Shah headshot

5 Biotechs That Escaped the Coronavirus Onslaught Last Week

by Kinjel Shah

Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.

Madeleine Johnson headshot

These 6 Drug Companies are Testing a Coronavirus Vaccine

by Madeleine Johnson

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Madeleine Johnson headshot

These 6 Drug Companies are Testing a Coronavirus Vaccine

by Madeleine Johnson

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Zacks Equity Research

Gilead Sciences (GILD) Surges: Stock Moves 6.6% Higher

by Zacks Equity Research

Gilead Sciences (GILD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Equity Research

5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates

by Zacks Equity Research

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

Zacks Equity Research

Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review

by Zacks Equity Research

Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.

Zacks Equity Research

J&J (JNJ) Signs Deal With HHS to Develop Coronavirus Vaccine

by Zacks Equity Research

Johnson & Johnson (JNJ) expands its agreement with BARDA, part of U.S. Department of Health and Human Services for accelerated development of a vaccine for the newly found coronavirus.

Sweta Jaiswal, FRM headshot

Can Biotech ETFs Gain on Mixed Q4 Earnings Results?

by Sweta Jaiswal, FRM

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.

Zacks Equity Research

Western Union (WU) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VAREX IMAGING (VREX) Q1 Earnings Miss Estimates

by Zacks Equity Research

VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Diodes (DIOD) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.

Zacks Equity Research

New Strong Sell Stocks for February 10th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences

Neena Mishra headshot

Can Biotech ETFs Continue to Soar in 2020?

by Neena Mishra

We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.

Zacks Equity Research

Company News for Feb 6, 2020

by Zacks Equity Research

Companies In The News Are: COTY, CPRI, HUM, GILD.

Sheraz Mian headshot

Coronavirus Starting to Weigh on 2020 Q1 Earnings Estimates

by Sheraz Mian

In addition to featuring fresh research reports on Exxon (XOM), Chevron (CVX), IBM (IBM) and others, today's Research Daily provides the Q4 earnings season update.

Zacks Equity Research

Regeneron Expands Agreement to Develop Coronavirus Therapy

by Zacks Equity Research

Regeneron (REGN) expands its agreement with U.S. Department of Health and Human Services for development of a therapy for newly found coronavirus.

Zacks Equity Research

Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod

by Zacks Equity Research

Many biotech bigwigs came out with their fourth-quarter numbers in the past week.

Zacks Equity Research

Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Disney, Chipotle, Ford, Gilead and Snap

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Disney, Chipotle, Ford, Gilead and Snap